ArticleNPJ vaccines2026
Evaluation of safety and efficacy of an auxotrophic aroA mutant live attenuated vaccine against piscine Streptococcus agalactiae infection.
Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CorAVeterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Streptococcus agalactiae is a major pathogen threatening global tilapia aquaculture, causing severe economic losses due to high mortality. The rise of antimicrobial resistance necessitates the development of effective vaccines for streptococcosis control. Here, we generated an auxotrophic mutant through the targeted deletion of the aroA gene, which encodes a key enzyme in aromatic amino acid biosynthesis. The aroA mutant (ΔaroA) exhibited reduced intracellular survival within macrophages, a phenotype that was not restored by supplementation with exogenous aromatic amino acids under our experimental conditions. These findings suggest that aroA contributes to intracellular survival through mechanisms extending beyond its role in aromatic amino acid biosynthesis. In zebrafish, Nile tilapia and mouse models, ΔaroA demonstrated stable attenuation, reduced endothelial cell damage, and mitigated blood-brain barrier disruption and neuroinflammation, confirming its safety. The ΔaroA strain provided dose-dependent protection against lethal S. agalactiae challenges in both tilapia and mice, with 100% protection in tilapia conferred at a dose of 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.